Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
37.44
-0.17 (-0.45%)
At close: Apr 9, 2026, 4:00 PM EDT
37.42
-0.02 (-0.05%)
After-hours: Apr 9, 2026, 5:33 PM EDT
Novo Nordisk Employees
Novo Nordisk had 69,505 employees as of December 31, 2025. The number of employees decreased by 7,844 or -10.14% compared to the previous year.
Employees
69,505
Change (1Y)
-7,844
Growth (1Y)
-10.14%
Revenue / Employee
$699,061
Profits / Employee
$231,692
Market Cap
165.39B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 69,505 | -7,844 | -10.14% |
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
| Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
| Dec 31, 2019 | 43,258 | 56 | 0.13% |
| Dec 31, 2018 | 43,202 | 520 | 1.22% |
| Dec 31, 2017 | 42,682 | 711 | 1.69% |
| Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
| Dec 31, 2015 | 40,638 | -319 | -0.78% |
| Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
| Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
| Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
| Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
| Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
| Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
| Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
| Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
| Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
| Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
| Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
| Dec 31, 2003 | 18,756 | 751 | 4.17% |
| Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
| Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
| Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
| Dec 31, 1999 | 11,994 | 345 | 2.96% |
| Dec 31, 1998 | 11,649 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
NVO News
- 1 day ago - Asia’s flood of cheap Ozempic generics opens gates to weight-loss abuse - South China Morning Post
- 1 day ago - Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker? - The Motley Fool
- 1 day ago - 3 Absurdly Cheap Dividend Stocks to Buy in April 2026 - The Motley Fool
- 1 day ago - A high dose of Wegovy will cost $50 less than Zepbound - MarketWatch
- 2 days ago - NVO: Novo Nordisk Launches Higher Dose Wegovy in the U.S. - GuruFocus
- 2 days ago - Can Wegovy HD 7.2 mg drive Novo Nordisk's obesity drug rebound? - Invezz
- 2 days ago - Novo Nordisk Unveils $399 Wegovy HD, Undercutting Lilly By About 40% - GuruFocus
- 2 days ago - Novo Nordisk Launches Higher-Dose Wegovy Weight-Loss Shot in U.S. - WSJ